Exagen(XGN) - 2024 Q3 - Quarterly Results

Exagen Inc. Reports Third Quarter 2024 Results Expanded AVISE® CTD trailing twelve-month average selling price Reduced Adjusted EBITDA loss for first three quarters of 2024 Revenue in line with expectations, excluding one-time adjustments November 12, 2024 Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2024 and recent corporate updates. | --- | --- | --- | --- | --- | --- | --- | --- | -- ...